Dr. Baram is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
834 Walnut St
Ste 650
Philadelphia, PA 19107Phone+1 215-955-5161Fax+1 215-923-6003- Is this information wrong?
Education & Training
- Brown UniversityFellowship, Pulmonary Disease and Critical Care Medicine, 2002 - 2005
- Christiana Care Health ServicesResidency, Internal Medicine/Emergency Medicine, 1997 - 2002
- Sidney Kimmel Medical College at Thomas Jefferson UniversityClass of 1997
Certifications & Licensure
- PA State Medical License 2006 - 2024
- DE State Medical License 1999 - 2009
- RI State Medical License 2003 - 2006
- MA State Medical License 2003 - 2004
- American Board of Internal Medicine Critical Care Medicine
- American Board of Internal Medicine Pulmonary Disease
Clinical Trials
- Convalescent Plasma for the Treatment of COVID-19 Start of enrollment: 2020 Apr 15
- Trial of Therapeutic Hypothermia in Patients With ARDS Start of enrollment: 2021 Jun 29
Roles: Contact, Principal Investigator
- Novel Experimental COVID-19 Therapies Affecting Host Response Start of enrollment: 2021 Jul 15
Roles: Contact
Publications & Presentations
PubMed
- 32 citationsNoninvasive hemodynamic monitoring in the intensive care unit.Paul E. Marik, Michael Baram
Critical Care Clinics. 2007-07-01 - 9 citationsOutcomes of extracorporeal membrane oxygenation in influenza versus COVID-19 during the first wave of COVID-19.Cameron Blazoski, Michael Baram, Qiong Yang, Hitoshi Hirose
Journal of Cardiac Surgery. 2021-08-09 - 890 citationsDoes Central Venous Pressure Predict Fluid Responsiveness?: A Systematic Review of the Literature and the Tale of Seven MaresPaul E. Marik, Michael Baram, Bobbak Vahid
Chest. 2008-07-01
Press Mentions
- COVID-19 Trials Opening at Accelerated RateMay 5th, 2020
- Biohaven Receives FDA May Proceed Letter to Begin Phase 2 Trial of Intranasal Vazegepant to Treat Lung Inflammation After COVID-19 InfectionApril 9th, 2020
Hospital Affiliations
- Thomas Jefferson University HospitalPhiladelphia, Pennsylvania
- Jefferson Stratford HospitalStratford, New Jersey
- Jefferson Abington HealthAbington, Pennsylvania
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: